Amylyx Pharmaceuticals Inc (AMLX) AI Stock Analysis

• Market Cap: $1.32B
• Dividend Yield: N/A
• Average Volume (3M): 1.34M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.57
• Revenue Growth: -100.34%
• EPS Growth: 52.85%
• Country: US
• Employees: 123
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.37
• Shares Outstanding: 109,819,570
• 10 Day Avg. Volume: 1,311,267
• 30 Day Avg. Volume: 1,341,052
• PEG Ratio: <0.01
• Price to Book (P/B): 1.56
• Price to Sales (P/S): 2.95
• P/FCF Ratio: -1.53
• Enterprise Value/Market Cap: 0.71
• Enterprise Value/Revenue: -1.40K
• Enterprise Value/Gross Profit: -45.03
• Enterprise Value/Ebitda: -6.05
• 1Y Price Target: $20.14
• Price Target Upside: 70.25% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: $12.00 ▲(1.44% Upside)

The score is held back primarily by weak financial performance—steep revenue deterioration, large losses, and sustained cash burn—partly offset by low leverage and the cash position highlighted on the earnings call. Technicals are mixed with weak short-term trend and negative MACD, while valuation is constrained by negative earnings (negative P/E).

Positive Factors

Low Leverage / Strong Balance Sheet

Extremely low debt relative to equity provides durable financial flexibility to fund clinical programs, tolerate trial setbacks, and avoid immediate reliance on debt financing. This equity cushion supports long-term R&D investment and strategic optionality through 2-6 months and beyond.

Substantial Cash Runway

A large cash balance and recent $191M offering materially extend runway into 2028, reducing near-term financing pressure. This allows management to advance Phase III and IND-enabling programs and absorb development timing variability without immediate dilution or sales pressure.

Pipeline Expansion & Partnered Discovery

Selection of AMX0318 and the Gubra collaboration meaningfully expands the GLP-1 pathway franchise beyond avexitide, diversifying the pipeline. Partner milestone structure de-risks preclinical costs and aligns incentives, increasing long-term product optionality if programs advance.

Negative Factors

Sharp Revenue Collapse

Revenue has deteriorated dramatically and profitability is highly volatile, indicating the current business model does not cover costs. Persistent revenue instability reduces visibility, raises reliance on successful trial outcomes, and weakens long-term earnings quality absent new commercial launches.

Sustained Cash Burn

Consistently negative operating and free cash flow demonstrate structural cash consumption from R&D and trials. Continued burn increases dependency on cash reserves or future financing, elevating dilution risk and constraining the firm's ability to scale operations if development timelines extend.

Phase III Enrollment Delay

A delayed Phase III enrollment pushes pivotal readouts and potential approval timelines, increasing trial costs and prolonging time to revenue. Such execution slippage materially raises program risk, can consume runway, and may weaken competitive positioning in the PBH market over the medium term.

Amylyx Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Amylyx Pharmaceuticals generates revenue primarily through the commercialization of its therapeutic products, particularly AMX0035, which has received regulatory approval for use in ALS patients. The company may also explore partnerships with larger pharmaceutical firms for co-development or licensing agreements to expand its product offerings and market reach. Additionally, revenue can be supplemented through grants and funding from governmental and non-governmental organizations aimed at fostering innovation in the biotech sector. As Amylyx progresses through clinical trials and achieves regulatory milestones, it may also benefit from milestone payments from partners, further contributing to its earnings.

Amylyx Pharmaceuticals Inc Financial Statement Overview

Summary

Amylyx Pharmaceuticals is facing significant financial challenges, with declining revenues and substantial operational losses reflected in negative profit margins. The balance sheet shows a relatively low level of debt and a strong equity ratio, although historical negative equity points to potential financial instability. Cash flow analysis reveals persistent cash generation issues, which could impact future operational sustainability.

Income Statement

The company's revenue showed a significant decrease from 2023 to 2024, indicating a revenue growth rate of -77.05%. Despite having a gross profit margin of 51.76% in 2024, the net profit margin was highly negative at -345.20%, reflecting substantial operational losses. The EBIT and EBITDA margins were also negative, highlighting ongoing profitability challenges.

Balance Sheet

Amylyx Pharmaceuticals maintains a low debt-to-equity ratio of 0.01, suggesting minimal reliance on debt. However, the company has a strong equity ratio of 85.10%, indicating that a majority of the assets are financed by shareholders' equity. Despite this, the company has consistently reported negative equity in previous years, pointing to financial instability risks.

Cash Flow

The company experienced a decline in free cash flow from 2023 to 2024, with a negative growth rate of -1671.46%. The operating cash flow to net income ratio is negative, reflecting operational inefficiencies. This indicates ongoing cash flow challenges, as the company is not generating sufficient cash from operations to cover its expenses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	-665.00K	87.37M	380.79M	22.23M	0.00	650.00K
Gross Profit	-20.66M	45.22M	355.35M	19.24M	0.00	-23.94M
EBITDA	-153.71M	-290.98M	39.89M	-200.85M	-82.64M	-39.00M
Net Income	-149.28M	-301.74M	49.27M	-198.38M	-87.93M	-42.28M
Balance Sheet
Total Assets	362.74M	193.63M	517.45M	391.45M	105.61M	14.10M
Cash, Cash Equivalents and Short-Term Investments	343.99M	176.50M	371.36M	346.94M	96.12M	12.88M
Total Debt	5.93M	1.98M	4.24M	6.28M	0.00	1.43M
Total Liabilities	30.75M	28.87M	84.02M	50.85M	256.78M	80.83M
Stockholders Equity	332.00M	164.76M	433.43M	340.61M	-151.17M	-66.72M
Cash Flow
Free Cash Flow	-154.52M	-167.80M	10.68M	-182.40M	-75.15M	-36.85M
Operating Cash Flow	-154.45M	-167.65M	11.92M	-179.87M	-74.80M	-36.70M
Investing Cash Flow	49.55M	75.65M	92.05M	-238.99M	-46.41M	-151.00K
Financing Cash Flow	257.35M	348.00K	3.54M	431.79M	158.51M	46.82M

Amylyx Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 11.83
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AMLX, the sentiment is Negative. The current price of 11.83 is below the 20-day moving average (MA) of 12.20, below the 50-day MA of 13.12, and above the 200-day MA of 9.25, indicating a neutral trend. The MACD of -0.47 indicates Positive momentum. The RSI at 40.92 is Neutral, neither overbought nor oversold. The STOCH value of 49.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AMLX.

Amylyx Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	81 Outperform	$2.16B	11.93	25.93%	―	21.13%	50.86%
DNTH	61 Neutral	$1.63B	-10.92	-28.57%	―	-42.64%	-39.78%
PHVS	56 Neutral	$1.60B	-7.77	-51.81%	―	―	-20.08%
BCRX	55 Neutral	$1.67B	-161.10	―	―	45.38%	92.85%
AMLX	53 Neutral	$1.32B	-6.57	-56.52%	―	-100.34%	52.85%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BHVN	44 Neutral	$1.56B	-1.50	-522.08%	―	―	18.76%

Amylyx Pharmaceuticals Inc Corporate Events

Amylyx Advances AMX0318 as New Rare-Disease Candidate

On January 8, 2026, Amylyx Pharmaceuticals selected AMX0318, a long-acting GLP-1 receptor antagonist discovered under its collaboration with peptide drug specialist Gubra A/S, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a $4 million milestone payment and positioning Gubra to earn more than $50 million in additional development and commercialization milestones plus mid-single-digit royalties on worldwide sales. The company also updated its corporate presentation in January 2026 to highlight a growing rare-disease pipeline led by avexitide, which is in a Phase 3 LUCIDITY trial for PBH with topline data expected in the third quarter of 2026 and a potential 2027 launch, while earlier clinical data have shown avexitide can sharply reduce hypoglycemic events in PBH patients, underscoring Amylyx’s strategic push to build a leading franchise in GLP-1 pathway modulation for underserved endocrine and neurodegenerative indications.

The most recent analyst rating on (AMLX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Amylyx Pharmaceuticals Inc stock, see the AMLX Stock Forecast page.